Advanced drug delivery reviews最新文献_第4页

Gas-based therapeutics and delivery platforms in cancer immunotherapy 肿瘤免疫治疗中的气体疗法和输送平台

IF 17.6 1区医学 Q1 PHARMACOLOGY & PHARMACY

Advanced drug delivery reviews

Pub Date : 2026-02-01 Epub Date: 2025-12-06 DOI: 10.1016/j.addr.2025.115746

Van-Anh Thi Nguyen , Chieh-Cheng Huang , Yunching Chen

Gas-based therapeutics are emerging as a promising strategy in cancer immunotherapy. Small gaseous signaling molecules such as nitric oxide (NO), carbon monoxide (CO), hydrogen sulfide (H₂S), and oxygen (O₂) efficiently penetrate tumor tissues and modulate diverse immune pathways. These therapeutic gases can relieve tumor hypoxia, enhance immune cell infiltration, induce immunogenic cancer cell death, and suppress immunosuppressive signaling within the tumor microenvironment (TME). Therefore, they potentiate immune checkpoint blockade and other immunotherapies while overcoming key barriers to immune evasion. Despite this promise, the clinical translation of gas-based therapies faces significant challenges, including short half-lives, systemic toxicity, and lack of spatiotemporal control. To address these limitations, a variety of delivery platforms have been developed—from nanocarriers and injectable hydrogels to inhalable and oral prodrug formulations and stimuli-responsive systems—that enable safe, tumor-targeted, and controlled release of therapeutic gases. Such engineered strategies maximize antitumor efficacy while minimizing off-target effects. This review highlights the immunomodulatory roles of therapeutic gases, examines state-of-the-art delivery technologies, and discusses how these advances lay the foundation for precision gas immunotherapy to unlock the clinical potential of gaseous immunomodulators in cancer treatment.

基于气体的治疗方法正在成为一种有前景的癌症免疫治疗策略。小的气体信号分子如一氧化氮（NO）、一氧化碳（CO）、硫化氢（H2S）和氧（O2）有效地渗透肿瘤组织并调节多种免疫途径。这些治疗气体可以缓解肿瘤缺氧，增强免疫细胞浸润，诱导免疫原性癌细胞死亡，抑制肿瘤微环境（tumor microenvironment， TME）内的免疫抑制信号。因此，它们增强了免疫检查点封锁和其他免疫疗法，同时克服了免疫逃避的关键障碍。尽管前景光明，但气体疗法的临床转化面临着重大挑战，包括半衰期短、全身毒性和缺乏时空控制。为了解决这些限制，已经开发了各种递送平台-从纳米载体和可注射水凝胶到可吸入和口服前药制剂和刺激反应系统-使治疗气体的安全，肿瘤靶向和控制释放。这种工程策略最大限度地提高了抗肿瘤效果，同时最大限度地减少了脱靶效应。这篇综述强调了治疗气体的免疫调节作用，检查了最先进的输送技术，并讨论了这些进步如何为精确气体免疫治疗奠定基础，以释放气体免疫调节剂在癌症治疗中的临床潜力。

{"title":"Gas-based therapeutics and delivery platforms in cancer immunotherapy","authors":"Van-Anh Thi Nguyen , Chieh-Cheng Huang , Yunching Chen","doi":"10.1016/j.addr.2025.115746","DOIUrl":"10.1016/j.addr.2025.115746","url":null,"abstract":"<div><div>Gas-based therapeutics are emerging as a promising strategy in cancer immunotherapy. Small gaseous signaling molecules such as nitric oxide (NO), carbon monoxide (CO), hydrogen sulfide (H<sub>2</sub>S), and oxygen (O<sub>2</sub>) efficiently penetrate tumor tissues and modulate diverse immune pathways. These therapeutic gases can relieve tumor hypoxia, enhance immune cell infiltration, induce immunogenic cancer cell death, and suppress immunosuppressive signaling within the tumor microenvironment (TME). Therefore, they potentiate immune checkpoint blockade and other immunotherapies while overcoming key barriers to immune evasion. Despite this promise, the clinical translation of gas-based therapies faces significant challenges, including short half-lives, systemic toxicity, and lack of spatiotemporal control. To address these limitations, a variety of delivery platforms have been developed—from nanocarriers and injectable hydrogels to inhalable and oral prodrug formulations and stimuli-responsive systems—that enable safe, tumor-targeted, and controlled release of therapeutic gases. Such engineered strategies maximize antitumor efficacy while minimizing off-target effects. This review highlights the immunomodulatory roles of therapeutic gases, examines state-of-the-art delivery technologies, and discusses how these advances lay the foundation for precision gas immunotherapy to unlock the clinical potential of gaseous immunomodulators in cancer treatment.</div></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"229 ","pages":"Article 115746"},"PeriodicalIF":17.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145689331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Perspectives and trends in gas delivery systems based on ultrasound responsive nanomaterials for cancer therapy 基于超声响应纳米材料的气体输送系统用于癌症治疗的前景和趋势

IF 17.6 1区医学 Q1 PHARMACOLOGY & PHARMACY

Advanced drug delivery reviews

Pub Date : 2026-02-01 Epub Date: 2025-12-04 DOI: 10.1016/j.addr.2025.115747

Jooho Moon , Hanhee Cho , Jeonghun Yu , Hyuncheol Kim , Kwangmeyung Kim

Gas-based therapeutic strategies (e.g., nitric oxide and carbon dioxide delivery) have shown promising potential for modulating the tumor microenvironment and enhancing anticancer efficacy. However, their clinical translation is limited by their poor spatiotemporal control, systemic toxicity, and limited tumor selectivity. As a powerful alternative, nanomaterial-based gas delivery systems offer improved stability, targeted accumulation, and programmable release in response to tumor-specific stimuli. Among various triggering methods, ultrasound has received particular attention because of its noninvasive nature, deep tissue penetration, and ability to locally activate nanocarriers. This review highlights the recent advances in ultrasound-triggered gas-generating delivery systems, including their design principles, gas-generating mechanisms, and representative nanoplatforms. The mechanistic insights into ultrasound-induced cavitation, thermal effects, and sonodynamic activation are discussed in the context of controlled gas release and drug delivery. Moreover, the therapeutic applications of these systems in solid tumors and metastatic lesions are summarized, and combination strategies integrating ultrasound-triggered gas release with chemotherapy, immunotherapy, or phototherapy are outlined. Finally, the current challenges and future perspectives for clinical translation are addressed, focusing on improving safety, scalability, and patient-specific tailoring. Ultrasound-responsive gas-generating delivery systems represent a promising approach for spatiotemporally controlled cancer therapy.

基于气体的治疗策略（例如，一氧化氮和二氧化碳输送）在调节肿瘤微环境和增强抗癌功效方面显示出良好的潜力。然而，它们的临床转化受到其较差的时空控制、全身毒性和有限的肿瘤选择性的限制。作为一种强大的替代方案，基于纳米材料的气体输送系统提供了更好的稳定性、靶向积累和可编程释放，以响应肿瘤特异性刺激。在各种触发方法中，超声因其非侵入性、深入组织和局部激活纳米载体的能力而受到特别关注。本文综述了超声触发产气输送系统的最新进展，包括其设计原理、产气机制和代表性纳米平台。在受控气体释放和药物传递的背景下，讨论了超声诱导空化、热效应和声动力激活的机理。此外，总结了这些系统在实体瘤和转移性病变中的治疗应用，并概述了将超声触发气体释放与化疗、免疫治疗或光疗相结合的联合策略。最后，讨论了临床翻译目前面临的挑战和未来的前景，重点是提高安全性、可扩展性和针对患者的定制。超声响应气体产生输送系统代表了一种有前途的方法，用于时空控制癌症治疗。

{"title":"Perspectives and trends in gas delivery systems based on ultrasound responsive nanomaterials for cancer therapy","authors":"Jooho Moon , Hanhee Cho , Jeonghun Yu , Hyuncheol Kim , Kwangmeyung Kim","doi":"10.1016/j.addr.2025.115747","DOIUrl":"10.1016/j.addr.2025.115747","url":null,"abstract":"<div><div>Gas-based therapeutic strategies (e.g., nitric oxide and carbon dioxide delivery) have shown promising potential for modulating the tumor microenvironment and enhancing anticancer efficacy. However, their clinical translation is limited by their poor spatiotemporal control, systemic toxicity, and limited tumor selectivity. As a powerful alternative, nanomaterial-based gas delivery systems offer improved stability, targeted accumulation, and programmable release in response to tumor-specific stimuli. Among various triggering methods, ultrasound has received particular attention because of its noninvasive nature, deep tissue penetration, and ability to locally activate nanocarriers. This review highlights the recent advances in ultrasound-triggered gas-generating delivery systems, including their design principles, gas-generating mechanisms, and representative nanoplatforms. The mechanistic insights into ultrasound-induced cavitation, thermal effects, and sonodynamic activation are discussed in the context of controlled gas release and drug delivery. Moreover, the therapeutic applications of these systems in solid tumors and metastatic lesions are summarized, and combination strategies integrating ultrasound-triggered gas release with chemotherapy, immunotherapy, or phototherapy are outlined. Finally, the current challenges and future perspectives for clinical translation are addressed, focusing on improving safety, scalability, and patient-specific tailoring. Ultrasound-responsive gas-generating delivery systems represent a promising approach for spatiotemporally controlled cancer therapy.</div></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"229 ","pages":"Article 115747"},"PeriodicalIF":17.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145689330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Engineering tissue patterning in human stem cell-based embryo models 人类干细胞胚胎模型的工程组织模式

IF 17.6 1区医学 Q1 PHARMACOLOGY & PHARMACY

Advanced drug delivery reviews

Pub Date : 2026-02-01 Epub Date: 2025-12-20 DOI: 10.1016/j.addr.2025.115765

Ella G. Lambert , Sara Romanazzo , Peter L.H. Newman , Kristopher A. Kilian

Human embryonic development is challenging to study in vitro as animal models inadequately represent human biology, while use of natural human embryos is both ethically and technically limited. Stem cell-based embryo models (SCBEMs) have emerged as a powerful alternative, enabling faithful recapitulation of early human development. However, current approaches predominantly rely on stochastic self-organisation with globally delivered signals, producing variable and often non-recapitulative structures. This review addresses this gap by introducing the first engineering-anchored taxonomy of human SCBEMs, systematically organizing the literature by their underlying technical platform rather than biological outcome alone. We demonstrate how five key engineering approaches – micropatterning, biomaterials, microwells, microfluidics, and dynamic culture – constrain morpho-and-histogenic patterning to determine developmental fidelity. We identify metabolic constraints limiting current models to ∼1 mm diameter as the primary bottleneck and demonstrate how vascular engineering and perfusion systems offer solutions. Finally, we propose standardisation metrics linking technical parameters to biological outcomes and establish an ethical framework defined by engineering choices.

人类胚胎发育的体外研究具有挑战性，因为动物模型不能充分代表人类生物学，而天然人类胚胎的使用在伦理和技术上都受到限制。基于干细胞的胚胎模型（SCBEMs）已经成为一种强大的替代方案，能够忠实地再现早期人类发育。然而，目前的方法主要依赖于具有全局传递信号的随机自组织，产生可变且通常是非概括的结构。本综述通过引入第一个以工程为基础的人类方案分类法来解决这一差距，系统地根据其潜在的技术平台而不是单独的生物学结果组织文献。我们展示了五种关键的工程方法——微模式、生物材料、微孔、微流体和动态培养——如何约束形态和组织结构模式来确定发育保真度。我们确定代谢限制将当前模型限制在1毫米直径为主要瓶颈，并展示血管工程和灌注系统如何提供解决方案。最后，我们提出了将技术参数与生物学结果联系起来的标准化指标，并建立了一个由工程选择定义的伦理框架。

{"title":"Engineering tissue patterning in human stem cell-based embryo models","authors":"Ella G. Lambert , Sara Romanazzo , Peter L.H. Newman , Kristopher A. Kilian","doi":"10.1016/j.addr.2025.115765","DOIUrl":"10.1016/j.addr.2025.115765","url":null,"abstract":"<div><div>Human embryonic development is challenging to study in vitro as animal models inadequately represent human biology, while use of natural human embryos is both ethically and technically limited. Stem cell-based embryo models (SCBEMs) have emerged as a powerful alternative, enabling faithful recapitulation of early human development. However, current approaches predominantly rely on stochastic self-organisation with globally delivered signals, producing variable and often non-recapitulative structures. This review addresses this gap by introducing the first engineering-anchored taxonomy of human SCBEMs, systematically organizing the literature by their underlying technical platform rather than biological outcome alone. We demonstrate how five key engineering approaches – micropatterning, biomaterials, microwells, microfluidics, and dynamic culture – constrain morpho-and-histogenic patterning to determine developmental fidelity. We identify metabolic constraints limiting current models to ∼1 mm diameter as the primary bottleneck and demonstrate how vascular engineering and perfusion systems offer solutions. Finally, we propose standardisation metrics linking technical parameters to biological outcomes and establish an ethical framework defined by engineering choices.</div></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"229 ","pages":"Article 115765"},"PeriodicalIF":17.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145784473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical translation and landscape of superparamagnetic iron oxide nanoparticles 超顺磁性氧化铁纳米颗粒的临床转化和景观

IF 17.6 1区医学 Q1 PHARMACOLOGY & PHARMACY

Advanced drug delivery reviews

Pub Date : 2026-02-01 Epub Date: 2025-12-06 DOI: 10.1016/j.addr.2025.115756

Yanchen Li, Roman A. Barmin, Rui Zhang, Fabian Kiessling, Twan Lammers, Roger M. Pallares

Since their initial clinical approval as liver imaging agents nearly three decades ago, superparamagnetic iron oxide nanoparticles (SPIONs) have evolved beyond diagnostic imaging to include also therapeutic and theranostic applications. Their clinical utility in both diagnosis and therapy depends on a combination of intrinsic physicochemical properties and in vivo behaviors, such as biodistribution and pharmacokinetics. These attributes enable specific applications, depending on the mechanisms of action and route of administration. For example, nanoparticle degradation can support anemia treatments. Tissue-specific retention in fenestrated organs and pathological tissues after systemic administration allows for imaging of the liver and inflammation sites, and image-guided therapy. Local delivery enables applications such as sentinel lymph node mapping and localized tumor thermal ablation. At the same time, these properties also constrain SPIONs from broader use as universal nanodiagnostic and theranostic agents. This review provides an overview of the current clinical landscape of superparamagnetic iron oxide nanoparticles, identifies shared features that have facilitated their successful translation, and discusses the critical challenges that must be addressed to enable wider clinical adoption.

超顺磁性氧化铁纳米颗粒（SPIONs）自近30年前首次被临床批准为肝脏显像剂以来，已经从诊断性成像发展到治疗性和治疗性应用。它们在诊断和治疗中的临床应用取决于内在的物理化学性质和体内行为的结合，如生物分布和药代动力学。这些属性启用特定的应用程序，具体取决于操作机制和管理路径。例如，纳米颗粒降解可以支持贫血治疗。系统给药后，组织特异性滞留在开窗器官和病理组织中，可以对肝脏和炎症部位进行成像，并进行图像引导治疗。局部递送使前哨淋巴结定位和局部肿瘤热消融等应用成为可能。同时，这些特性也限制了SPIONs作为通用纳米诊断和治疗药物的广泛应用。这篇综述概述了超顺磁性氧化铁纳米颗粒目前的临床前景，确定了促进其成功转化的共同特征，并讨论了必须解决的关键挑战，以使其更广泛的临床应用。

{"title":"Clinical translation and landscape of superparamagnetic iron oxide nanoparticles","authors":"Yanchen Li, Roman A. Barmin, Rui Zhang, Fabian Kiessling, Twan Lammers, Roger M. Pallares","doi":"10.1016/j.addr.2025.115756","DOIUrl":"10.1016/j.addr.2025.115756","url":null,"abstract":"<div><div>Since their initial clinical approval as liver imaging agents nearly three decades ago, superparamagnetic iron oxide nanoparticles (SPIONs) have evolved beyond diagnostic imaging to include also therapeutic and theranostic applications. Their clinical utility in both diagnosis and therapy depends on a combination of intrinsic physicochemical properties and in vivo behaviors, such as biodistribution and pharmacokinetics. These attributes enable specific applications, depending on the mechanisms of action and route of administration. For example, nanoparticle degradation can support anemia treatments. Tissue-specific retention in fenestrated organs and pathological tissues after systemic administration allows for imaging of the liver and inflammation sites, and image-guided therapy. Local delivery enables applications such as sentinel lymph node mapping and localized tumor thermal ablation. At the same time, these properties also constrain SPIONs from broader use as universal nanodiagnostic and theranostic agents. This review provides an overview of the current clinical landscape of superparamagnetic iron oxide nanoparticles, identifies shared features that have facilitated their successful translation, and discusses the critical challenges that must be addressed to enable wider clinical adoption.</div></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"229 ","pages":"Article 115756"},"PeriodicalIF":17.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145689332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advances in numerical simulation of magnetically guided drug delivery systems and applications 磁导给药系统数值模拟及其应用的最新进展

IF 17.6 1区医学 Q1 PHARMACOLOGY & PHARMACY

Advanced drug delivery reviews

Pub Date : 2026-02-01 Epub Date: 2025-12-04 DOI: 10.1016/j.addr.2025.115745

Zhenyang Xu , Tayebeh Mousavi , Xiaoli Liu , Anita Ahmadi Birjandi , Maya Thanou , Haiming Fan , Mark Ainslie

Magnetically guided drug delivery (MGDD) employs magnetic forces acting on magnetically responsive drug delivery systems (DDS) to direct therapeutic agents toward diseased regions, thereby enhancing local drug accumulation while minimising systemic side effects. Numerical simulation, grounded in the physical principles governing MGDD, provides an efficient computational framework for modelling and visualising these processes, thereby accelerating progress in MGDD research. This review comprehensively summarises recent advances in the application of numerical simulation to MGDD, including magnet design and analysis, multiscale modelling of DDS transport processes at macroscopic, mesoscopic, and microscopic scales, and DDS design and evaluation. In addition, the integration of optimisation algorithms and artificial intelligence (AI) with numerical simulation for MGDD is discussed. Finally, future perspectives are presented, emphasising the development of high-fidelity, multiscale, and AI-driven simulation frameworks to accelerate clinical translation toward personalised, efficient MGDD-based therapeutic systems.

磁导给药（MGDD）利用磁力作用于磁响应药物给药系统（DDS），将治疗剂导向病变区域，从而增强局部药物积累，同时最大限度地减少全身副作用。数值模拟以控制MGDD的物理原理为基础，为这些过程的建模和可视化提供了有效的计算框架，从而加速了MGDD研究的进展。本文综述了近年来数值模拟技术在磁体设计与分析、DDS输运过程宏观、介观和微观多尺度模拟、DDS设计与评价等方面的研究进展。此外，还讨论了优化算法和人工智能（AI）与MGDD数值模拟的集成。最后，提出了未来的展望，强调高保真、多尺度和人工智能驱动的模拟框架的发展，以加速向个性化、高效的基于mddd的治疗系统的临床转化。

{"title":"Recent advances in numerical simulation of magnetically guided drug delivery systems and applications","authors":"Zhenyang Xu , Tayebeh Mousavi , Xiaoli Liu , Anita Ahmadi Birjandi , Maya Thanou , Haiming Fan , Mark Ainslie","doi":"10.1016/j.addr.2025.115745","DOIUrl":"10.1016/j.addr.2025.115745","url":null,"abstract":"<div><div>Magnetically guided drug delivery (MGDD) employs magnetic forces acting on magnetically responsive drug delivery systems (DDS) to direct therapeutic agents toward diseased regions, thereby enhancing local drug accumulation while minimising systemic side effects. Numerical simulation, grounded in the physical principles governing MGDD, provides an efficient computational framework for modelling and visualising these processes, thereby accelerating progress in MGDD research. This review comprehensively summarises recent advances in the application of numerical simulation to MGDD, including magnet design and analysis, multiscale modelling of DDS transport processes at macroscopic, mesoscopic, and microscopic scales, and DDS design and evaluation. In addition, the integration of optimisation algorithms and artificial intelligence (AI) with numerical simulation for MGDD is discussed. Finally, future perspectives are presented, emphasising the development of high-fidelity, multiscale, and AI-driven simulation frameworks to accelerate clinical translation toward personalised, efficient MGDD-based therapeutic systems.</div></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"229 ","pages":"Article 115745"},"PeriodicalIF":17.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145673902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrating PROTAC-based targeted protein degradation with nanodelivery systems to overcome cancer therapeutic resistance 整合基于protac的靶向蛋白降解与纳米递送系统克服癌症治疗耐药性

IF 17.6 1区医学 Q1 PHARMACOLOGY & PHARMACY

Advanced drug delivery reviews

Pub Date : 2026-02-01 Epub Date: 2025-12-10 DOI: 10.1016/j.addr.2025.115755

Xinyu Gou , Shi He , Bilan Wang , Lingli Zhang , Yongzhong Cheng , Xiang Gao

Tumor drug resistance is a major challenge in cancer treatment, as traditional chemotherapeutic agents and small molecule inhibitors often become ineffective in targeting tumors due to drug resistance. Proteolysis Targeting Chimeras (PROTAC) technology, as a novel protein degradation method, provides a new insight into overcoming drug resistance in tumors with the assistance of nanodelivery systems. PROTAC is able to degrade rather than merely inhibit tumor-associated proteins, thus avoiding drug resistance caused by gene mutations, protein overexpression and conformational changes, demonstrating significant advantages in overcoming tumor resistance. First, PROTAC eliminates the biological activity of the target protein by directly degrading it, thus overcoming the limitation of traditional inhibitors, which are susceptible to mutations of the structure and activity of the target protein. Second, PROTAC molecules are highly versatile and flexible, and can target proteins that are difficult to target with conventional drugs, including enzymatically inactive proteins, transcription factors and oncogenic protein complexes. In addition, PROTAC technology, with the booster of nanodelivery systems, can effectively improve solubility and bioavailability, enhance targeting and delivery efficiency while improving its stability, and can be combined with other therapeutic methods to further enhance the therapeutic effect. The versatility of PROTAC makes it a highly promising option for overcoming tumor drug resistance, and their effectiveness has been validated in a variety of cancers, including breast cancer, prostate cancer, and leukemia. In this paper, we will review the recent progress of PROTAC technology in overcoming tumor drug resistance and briefly summarize the advantages and challenges of PROTAC technology combined with nanodelivery system, hoping to provide valuable references for researchers in related fields.

肿瘤耐药是肿瘤治疗的主要挑战，传统的化疗药物和小分子抑制剂往往由于耐药而无法靶向肿瘤。蛋白质水解靶向嵌合体（Proteolysis Targeting Chimeras， PROTAC）技术作为一种新的蛋白质降解方法，为利用纳米递送系统克服肿瘤耐药提供了新的思路。PROTAC能够降解而不仅仅是抑制肿瘤相关蛋白，从而避免了基因突变、蛋白过表达和构象改变引起的耐药，在克服肿瘤耐药方面具有显著优势。首先，PROTAC通过直接降解目标蛋白来消除其生物活性，从而克服了传统抑制剂易受目标蛋白结构和活性突变的限制。其次，PROTAC分子具有高度的通用性和灵活性，可以靶向传统药物难以靶向的蛋白质，包括酶失活蛋白、转录因子和致癌蛋白复合物。此外，PROTAC技术在纳米递送系统的助推下，可有效提高溶解度和生物利用度，在提高稳定性的同时增强靶向性和递送效率，并可与其他治疗方法联合使用，进一步提高治疗效果。PROTAC的多功能性使其成为克服肿瘤耐药性的极有希望的选择，其有效性已在多种癌症中得到验证，包括乳腺癌，前列腺癌和白血病。本文将综述PROTAC技术在克服肿瘤耐药方面的最新进展，并简要总结PROTAC技术结合纳米给药系统的优势和挑战，希望为相关领域的研究人员提供有价值的参考。

{"title":"Integrating PROTAC-based targeted protein degradation with nanodelivery systems to overcome cancer therapeutic resistance","authors":"Xinyu Gou , Shi He , Bilan Wang , Lingli Zhang , Yongzhong Cheng , Xiang Gao","doi":"10.1016/j.addr.2025.115755","DOIUrl":"10.1016/j.addr.2025.115755","url":null,"abstract":"<div><div>Tumor drug resistance is a major challenge in cancer treatment, as traditional chemotherapeutic agents and small molecule inhibitors often become ineffective in targeting tumors due to drug resistance. Proteolysis Targeting Chimeras (PROTAC) technology, as a novel protein degradation method, provides a new insight into overcoming drug resistance in tumors with the assistance of nanodelivery systems. PROTAC is able to degrade rather than merely inhibit tumor-associated proteins, thus avoiding drug resistance caused by gene mutations, protein overexpression and conformational changes, demonstrating significant advantages in overcoming tumor resistance. First, PROTAC eliminates the biological activity of the target protein by directly degrading it, thus overcoming the limitation of traditional inhibitors, which are susceptible to mutations of the structure and activity of the target protein. Second, PROTAC molecules are highly versatile and flexible, and can target proteins that are difficult to target with conventional drugs, including enzymatically inactive proteins, transcription factors and oncogenic protein complexes. In addition, PROTAC technology, with the booster of nanodelivery systems, can effectively improve solubility and bioavailability, enhance targeting and delivery efficiency while improving its stability, and can be combined with other therapeutic methods to further enhance the therapeutic effect. The versatility of PROTAC makes it a highly promising option for overcoming tumor drug resistance, and their effectiveness has been validated in a variety of cancers, including breast cancer, prostate cancer, and leukemia. In this paper, we will review the recent progress of PROTAC technology in overcoming tumor drug resistance and briefly summarize the advantages and challenges of PROTAC technology combined with nanodelivery system, hoping to provide valuable references for researchers in related fields.</div></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"229 ","pages":"Article 115755"},"PeriodicalIF":17.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145717895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Spatial patterning strategies for liver tissue engineering: Biofabrication technologies and applications 肝组织工程的空间模式策略：生物制造技术和应用

IF 17.6 1区医学 Q1 PHARMACOLOGY & PHARMACY

Advanced drug delivery reviews

Pub Date : 2026-01-01 Epub Date: 2025-11-15 DOI: 10.1016/j.addr.2025.115737

Haram Nah , Ashlin R. Michell , Kerry M. Rogy, Owen J. Lally, Salman R. Khetani

The liver is composed of hepatocytes and non-parenchymal cells arranged in precise spatial patterns that enable more than 500 metabolic, synthetic, and detoxification functions. Replicating this hierarchical structure and dynamic multicellular organization is essential for applications in drug development and regenerative medicine. Here, we review biofabrication strategies that encode spatial control in engineered liver tissues. We begin with native hepatic architecture and cell sources, then evaluate self-assembled and engineered aggregates, soft lithography, electrospun scaffolds, three-dimensional bioprinting, and microfluidic systems in terms of their ability to capture physiological features such as zonation, polarity, and vascular or biliary networks. Hybrid approaches that integrate multiple modalities to enhance complexity and function are also highlighted. We next discuss how human liver models are advancing drug metabolism and toxicity screening, disease modeling, and potential therapeutic applications. Finally, we examine current limitations and future directions, emphasizing challenges of scalability, reproducibility, and standardization, along with emerging opportunities in volumetric bioprinting, machine learning–guided design, and regulatory qualification of liver microphysiological systems. Collectively, engineered liver models are poised to play an increasingly critical role in bridging in vitro and in vivo applications as advances in biofabrication bring them closer to clinical and regulatory translation.

肝脏由肝细胞和非实质细胞组成，它们以精确的空间模式排列，具有500多种代谢、合成和解毒功能。复制这种分层结构和动态多细胞组织对于药物开发和再生医学的应用至关重要。在这里，我们回顾了在工程肝组织中编码空间控制的生物制造策略。我们从天然肝脏结构和细胞来源开始，然后评估自组装和工程聚集体、软光刻、电纺丝支架、三维生物打印和微流体系统在捕捉生理特征（如分区、极性、血管或胆道网络）方面的能力。还强调了集成多种模式以增强复杂性和功能的混合方法。接下来，我们将讨论人类肝脏模型如何促进药物代谢和毒性筛选、疾病建模和潜在的治疗应用。最后，我们研究了当前的局限性和未来的方向，强调了可扩展性、可重复性和标准化方面的挑战，以及体积生物打印、机器学习指导设计和肝脏微生理系统监管资格方面的新机遇。总的来说，工程肝脏模型在体外和体内桥接应用中发挥着越来越重要的作用，因为生物制造的进步使它们更接近临床和调节翻译。

{"title":"Spatial patterning strategies for liver tissue engineering: Biofabrication technologies and applications","authors":"Haram Nah , Ashlin R. Michell , Kerry M. Rogy, Owen J. Lally, Salman R. Khetani","doi":"10.1016/j.addr.2025.115737","DOIUrl":"10.1016/j.addr.2025.115737","url":null,"abstract":"<div><div>The liver is composed of hepatocytes and non-parenchymal cells arranged in precise spatial patterns that enable more than 500 metabolic, synthetic, and detoxification functions. Replicating this hierarchical structure and dynamic multicellular organization is essential for applications in drug development and regenerative medicine. Here, we review biofabrication strategies that encode spatial control in engineered liver tissues. We begin with native hepatic architecture and cell sources, then evaluate self-assembled and engineered aggregates, soft lithography, electrospun scaffolds, three-dimensional bioprinting, and microfluidic systems in terms of their ability to capture physiological features such as zonation, polarity, and vascular or biliary networks. Hybrid approaches that integrate multiple modalities to enhance complexity and function are also highlighted. We next discuss how human liver models are advancing drug metabolism and toxicity screening, disease modeling, and potential therapeutic applications. Finally, we examine current limitations and future directions, emphasizing challenges of scalability, reproducibility, and standardization, along with emerging opportunities in volumetric bioprinting, machine learning–guided design, and regulatory qualification of liver microphysiological systems. Collectively, engineered liver models are poised to play an increasingly critical role in bridging in vitro and in vivo applications as advances in biofabrication bring them closer to clinical and regulatory translation.</div></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"228 ","pages":"Article 115737"},"PeriodicalIF":17.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145515994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Living materials for gas therapy 气体治疗用的生活材料

IF 17.6 1区医学 Q1 PHARMACOLOGY & PHARMACY

Advanced drug delivery reviews

Pub Date : 2026-01-01 Epub Date: 2025-11-15 DOI: 10.1016/j.addr.2025.115738

Pei Pan , Tao Liu , Lu Zhang , Xian-Zheng Zhang

The clinical translation of gas therapy, which employs medical gases such as nitric oxide (NO), carbon monoxide (CO), hydrogen sulfide (H₂S), hydrogen (H₂), and sulfur dioxide (SO₂), is mainly limited by the absence of delivery systems that can provide precise spatiotemporal control in complex pathological environments. While conventional nanocarriers have improved in gas delivery, they often suffer from limited biocompatibility, poor targeting, and insufficient responsiveness. Recently, living materials emerged as a promising and innovative paradigm. Engineered from biological entities such as bacteria, cells, and algae, or their biomimetic derivatives, these materials inherently exhibit bioactive functions, including disease tropism, immunomodulation, and dynamic responsiveness to microenvironmental cues, thereby enabling intelligent gas generation and controlled release. This review systematically summarizes recent advances in living material–based gas therapy, with emphasis on classification according to biological origin and engineering design principles. We further discuss their mechanisms, including genetic programming for autonomous gas production and hybrid architectures for stimuli-responsive release, and highlight their therapeutic efficacy in cancer, inflammatory diseases, and tissue regeneration. Finally, we outline the major challenges in biosafety and scalability, and provide forward-looking perspectives on the integration of synthetic biology and multimodal therapeutic strategies to advance the field of precision gas medicine.

使用医用气体如一氧化氮（NO）、一氧化碳（CO）、硫化氢（H2S）、氢气（H2）和二氧化硫（SO2）的气体疗法的临床转化主要受到缺乏能够在复杂病理环境中提供精确时空控制的输送系统的限制。虽然传统的纳米载体在气体输送方面有所改进，但它们往往存在生物相容性有限、靶向性差和响应性不足的问题。最近，生物材料作为一种有前途的创新范例出现了。这些材料由细菌、细胞和藻类等生物实体或其仿生衍生物改造而成，固有地表现出生物活性功能，包括疾病趋向性、免疫调节和对微环境线索的动态响应，从而实现智能气体产生和控制释放。本文系统地综述了基于生物材料的气体治疗的最新进展，重点介绍了基于生物起源和工程设计原则的分类。我们进一步讨论了它们的机制，包括自主产气的遗传编程和刺激反应释放的混合结构，并强调了它们在癌症、炎症性疾病和组织再生中的治疗功效。最后，我们概述了生物安全性和可扩展性方面的主要挑战，并就合成生物学和多模式治疗策略的整合提供了前瞻性观点，以推进精密气体医学领域的发展。

{"title":"Living materials for gas therapy","authors":"Pei Pan , Tao Liu , Lu Zhang , Xian-Zheng Zhang","doi":"10.1016/j.addr.2025.115738","DOIUrl":"10.1016/j.addr.2025.115738","url":null,"abstract":"<div><div>The clinical translation of gas therapy, which employs medical gases such as nitric oxide (NO), carbon monoxide (CO), hydrogen sulfide (H<sub>2</sub>S), hydrogen (H<sub>2</sub>), and sulfur dioxide (SO<sub>2</sub>), is mainly limited by the absence of delivery systems that can provide precise spatiotemporal control in complex pathological environments. While conventional nanocarriers have improved in gas delivery, they often suffer from limited biocompatibility, poor targeting, and insufficient responsiveness. Recently, living materials emerged as a promising and innovative paradigm. Engineered from biological entities such as bacteria, cells, and algae, or their biomimetic derivatives, these materials inherently exhibit bioactive functions, including disease tropism, immunomodulation, and dynamic responsiveness to microenvironmental cues, thereby enabling intelligent gas generation and controlled release. This review systematically summarizes recent advances in living material–based gas therapy, with emphasis on classification according to biological origin and engineering design principles. We further discuss their mechanisms, including genetic programming for autonomous gas production and hybrid architectures for stimuli-responsive release, and highlight their therapeutic efficacy in cancer, inflammatory diseases, and tissue regeneration. Finally, we outline the major challenges in biosafety and scalability, and provide forward-looking perspectives on the integration of synthetic biology and multimodal therapeutic strategies to advance the field of precision gas medicine.</div></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"228 ","pages":"Article 115738"},"PeriodicalIF":17.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145515997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Informing development of brain cancer therapies within "preclinical trials" using ex vivo patient tumors 为使用离体患者肿瘤进行“临床前试验”的脑癌治疗提供信息

IF 17.6 1区医学 Q1 PHARMACOLOGY & PHARMACY

Advanced drug delivery reviews

Pub Date : 2026-01-01 Epub Date: 2025-11-19 DOI: 10.1016/j.addr.2025.115736

Adebimpe Adefolaju , David E. Kram , Breanna Mann , Shawn Hingtgen , Andrew Satterlee

Brain and nervous system cancers account for only ∼1.3% of new cancer diagnoses but rank ninth in US cancer mortality, a disparity partly driven by limited therapeutic options and inadequate preclinical models that misrepresent a drug’s therapeutic potential. Considering that about 90% of drugs validated with these models fail in late-phase clinical trials, it is imperative to further scrutinize drugs in preclinical settings that better model relevant aspects of disease and treatment response. New paradigms must account for challenges unique to brain cancers such as lack of relevant biomarkers and both intra-disease and patient to patient heterogeneity, which cause treatments to be effective in a suboptimal proportion of the population. In this review, we investigate the current brain cancer drug development landscape, introduce a growing field of functional precision medicine, and propose the inclusion of “preclinical trials” that interrogate the effects of new therapies and drug delivery mechanisms on living patient tumors ex vivo. These preclinical trials respond to the FDA’s recent announcement to phase out and replace live animal testing with human-based lab models. Functional models can address heterogeneity and biomarker identification through accrual of living patient tumor tissue, preclinical drug sensitivity testing, identification of non-responders and resistance mechanisms, and development of functional predictive biomarkers and companion diagnostics. Because functional precision medicine stratification of clinical trials candidates has shown improved clinical trials outcome, using this paradigm earlier in drug development could enhance clinical trial success, leading to more FDA-approved drugs and therapeutic options for brain cancer patients.

脑和神经系统癌症仅占新癌症诊断的约1.3%，但在美国癌症死亡率中排名第九，这一差距的部分原因是有限的治疗选择和不充分的临床前模型，这些模型错误地反映了药物的治疗潜力。考虑到使用这些模型验证的药物中约有90%在后期临床试验中失败，因此有必要进一步审查临床前环境中的药物，以便更好地模拟疾病和治疗反应的相关方面。新的范式必须考虑脑癌特有的挑战，如缺乏相关的生物标志物，以及疾病内和患者之间的异质性，这导致治疗在人口的次优比例中有效。在这篇综述中，我们调查了目前脑癌药物的开发前景，介绍了一个不断发展的功能精准医学领域，并提出了包括“临床前试验”在内的新疗法和药物给药机制对活体肿瘤患者的影响。这些临床前试验是对FDA最近宣布逐步淘汰并用基于人类的实验室模型取代活体动物试验的回应。功能模型可以通过活体患者肿瘤组织的累积、临床前药物敏感性测试、无反应和耐药机制的识别以及功能预测性生物标志物和伴随诊断的发展来解决异质性和生物标志物鉴定。由于对临床试验候选者的功能精准医学分层已经显示出改善的临床试验结果，在药物开发的早期使用这种模式可以提高临床试验的成功率，从而为脑癌患者带来更多fda批准的药物和治疗选择。

{"title":"Informing development of brain cancer therapies within \"preclinical trials\" using ex vivo patient tumors","authors":"Adebimpe Adefolaju , David E. Kram , Breanna Mann , Shawn Hingtgen , Andrew Satterlee","doi":"10.1016/j.addr.2025.115736","DOIUrl":"10.1016/j.addr.2025.115736","url":null,"abstract":"<div><div>Brain and nervous system cancers account for only ∼1.3% of new cancer diagnoses but rank ninth in US cancer mortality, a disparity partly driven by limited therapeutic options and inadequate preclinical models that misrepresent a drug’s therapeutic potential. Considering that about 90% of drugs validated with these models fail in late-phase clinical trials, it is imperative to further scrutinize drugs in preclinical settings that better model relevant aspects of disease and treatment response. New paradigms must account for challenges unique to brain cancers such as lack of relevant biomarkers and both intra-disease and patient to patient heterogeneity, which cause treatments to be effective in a suboptimal proportion of the population. In this review, we investigate the current brain cancer drug development landscape, introduce a growing field of functional precision medicine, and propose the inclusion of “preclinical trials” that interrogate the effects of new therapies and drug delivery mechanisms on living patient tumors <em>ex vivo.</em> These preclinical trials respond to the FDA’s recent announcement to phase out and replace live animal testing with human-based lab models. Functional models can address heterogeneity and biomarker identification through accrual of living patient tumor tissue, preclinical drug sensitivity testing, identification of non-responders and resistance mechanisms, and development of functional predictive biomarkers and companion diagnostics. Because functional precision medicine stratification of clinical trials candidates has shown improved clinical trials outcome, using this paradigm earlier in drug development could enhance clinical trial success, leading to more FDA-approved drugs and therapeutic options for brain cancer patients.</div></div>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"228 ","pages":"Article 115736"},"PeriodicalIF":17.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145546274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

3D printing in theranostic applications 3D打印在治疗中的应用

IF 17.6 1区医学 Q1 PHARMACOLOGY & PHARMACY

Advanced drug delivery reviews

Pub Date : 2026-01-01 Epub Date: 2025-11-10 DOI: 10.1016/j.addr.2025.115733

Italo Rodrigo Calori, Ana Paula Pereira Guimaraes, Antonio Claudio Tedesco

Additive manufacturing has revolutionized conventional fabrication techniques, enabling the design of advanced theranostic platforms that integrates diagnostic and therapeutic functions within a single device. In this context, three-dimensional (3D) printing has emerged as a key technology for fabricating sophisticated theranostic solutions capable of effectively integrating diagnostic and therapeutic approaches. This review summarizes the recent use of 3D printing technologies in the field of theranostic, providing a comprehensive understanding of the state of the art and future perspectives. This review explores the design and fabrication of theranostic devices using a range of extrusion-based and light-based printing techniques including fused deposition modeling, stereolithography, and selective laser sintering. Furthermore, this review discuss the current challenges and limitations of the implementation of these technologies. Overall, this review provides insights into the potential and challenges of 3D printing for the advancement of theranostic strategies.

增材制造已经改变了传统的治疗方法，允许生产更复杂的设备，以满足不断发展的诊断和治疗需求。在这种情况下，三维（3D）打印已经成为生产个性化治疗的关键技术，能够有效地整合诊断和治疗方法。本文综述了近年来3D打印技术在治疗领域的应用，提供了对该技术现状和未来前景的全面了解。这篇综述探讨了使用一系列技术的治疗装置的设计和制造，包括基于挤压的印刷，熔融沉积建模，立体光刻和选择性激光烧结。此外，本综述还讨论了这些技术实施的当前挑战和局限性。最后，这篇综述提供了对3D打印的潜力和挑战的见解，以促进治疗策略。

引用次数: 0